Bayer faces Swiss criminal probe over cerivastatinBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7330.130b (Published 19 January 2002) Cite this as: BMJ 2002;324:130
- Fiona Fleck
Prosecutors in the Swiss canton of Ticino have opened a criminal inquiry into Bayer AG on suspicion of fraud and grievous bodily damage following the German pharmaceutical giant's controversial recall of its cholesterol drug cerivastatin sodium in August last year.
Cantonal prosecutor Nicola Respini told the BMJ on Friday that he had opened the investigation on 4 December after a patient taking cerivastatin (marketed as Lipobay …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial